A Phase 3 interventional study of Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose and Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg in Macular Edema Secondary to Retinal Vein Occlusion, sponsored by Bayer. Completed at 273 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Macular Edema by Bayer — none open to participants now, 1 under way, none of them phase 3. Macular Edema · Bayer.
Among the 16 studies in Macular Edema by Bayer, this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 2023, is one of 7 in phase 3, and was the 13th registered.
758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →None of the 16 studies in Macular Edema by Bayer is open now. The open studies under Macular Edema, anywhere →
Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 892 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 357 across the 10 interventional studies, 831 across the 6 observational. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
1 of the studies in Macular Edema by Bayer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06929143BayerA Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema | 2027-07-30 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Macular Edema by Bayer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).
In people with RVO, a blood vessel that carries blood away from the retina (vein) becomes blocked. The retina is the very back part of the eye. The blocked vein causes fluid and blood to leak into the retina and thereby causes a swelling of the macula (the center of the retina responsible for fine vision). This swelling is called macular edema.
When a vein in the retina is blocked, the levels of a protein called vascular endothelial growth factor (VEGF) rises. VEGF helps the growth of new blood vessels. This can lead to macular edema and may cause the vision to become blurry.
The study treatment intravitreal (IVT) aflibercept is given as an injection into the eye. It works by blocking VEGF and this can help repair vision problems related to RVO. IVT aflibercept is already available and is prescribed by doctors as the standard of care treatment for macula edema secondary to RVO. Standard of care is a treatment that medical experts consider most appropriate for a disease.
Standard of care is given every 4 weeks in people with macula edema secondary to RVO. While repeated injections of aflibercept may prevent worsening of vision, it may place a burden on the patient. However, a higher amount (8 mg) compared to the standard of care (2 mg) of IVT aflibercept is being tested in studies. This higher amount could be given less often. The amount of IVT aflibercept given is measured in milligrams, also known as mg.
The main purpose of this study is to learn how well a higher amount of the study treatment aflibercept works in people with macular edema secondary to RVO. To answer this, researchers will measure changes in vision called best corrected visual acuity (BCVA) in the study participants between study start and after 36 weeks of treatment. Changes will then be compared between those participants who received the higher amount of IVT aflibercept and those that received standard of care.
To learn how safe the study treatment is in the participants, the researchers will count the number of participants from study start and up to 64 weeks later that have:
"Adverse events" are any medical problems that the participants have during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think they might be related to the study treatments. An adverse event is considered "serious" when it leads to death, puts the participants' lives at risk, requires hospitalization, causes disability, causes a baby being born with medical problems or is otherwise medically important.
Dependent on the treatment group, the participants will either receive the higher amount of aflibercept or standard of care as an intravitreal injection for up to 60 weeks. The study will consist of a test (screening) phase, a treatment phase and an end of study phase. Each participant will be in the study for up to 64 weeks.
One visit to the study site is planned during the screening phase, followed by visits approximately every 4 weeks (16 in total) during treatment and one visit at the end of the study.
During the study, the study doctors and their team will:
In addition, participants will be asked to fill a questionnaire on vision-related quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Decrease in BCVA determined to be primarily the result of RVO in the study eye.
Exclusion Criteria:
Presence or history of the following ocular conditions:
Presence of the following ocular conditions at screening or baseline visit:
Prior treatment of the study eye with any of the following drugs (any route of ophthalmic administration) or procedures:
Prior treatment of the fellow eye with any of the following:
a. Gene therapy, or cell therapy in the fellow eye at any time.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Higher dose of aflibercept is administered with initial initiation doses intervals, followed by extension of treatment intervals and further adjustment of intervals according to treatment response.
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose · Drug: Sham · Diagnostic Test: Fluorescein
Higher dose of aflibercept is administered with initial initiation doses intervals, followed by extension of treatment intervals and further adjustment of intervals according to treatment response.
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose · Drug: Sham · Diagnostic Test: Fluorescein
Aflibercept 2 mg is administered by standard treatment intervals, followed by adjustment of treatment intervals according to treatment response.
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg · Diagnostic Test: Fluorescein
Intravitreally (IVT) injection.
Intravitreally (IVT) injection.
Sham procedure will be given on visits when an active injection is not planned.
Fluorescein 100 mg/mL solution for injection is a dye that makes the retinal vessels visible during FA examinations, and as such, it will be used as an auxiliary medicinal product (AxMP) in this periodic ophthalmic examination. This medicine is for diagnostic use only. It is not used to treat any condition.
Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 36
BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)
Time frame: At Week 36
Number of Active Injections From Baseline to Week 64
Active injections refer to the number of injections that were actually administered, as opposed to the number of planned injections.
Time frame: From baseline to Week 64
Number of Active Injections From Baseline to Week 36
Active injections refer to the number of injections that were actually administered, as opposed to the number of planned injections.
Time frame: From baseline to Week 36
Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 44*
BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity). \*This endpoint was only measured for the 8q8/5 and 2q4 groups
Time frame: At Week 44
Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 64
BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)
Time frame: At Week 64
Participants Gaining at Least 15 Letters in BCVA From Baseline at Weeks 36 and 64
Time frame: From baseline at Weeks 36 and 64
Participants Achieving an ETDRS Letter Score of at Least 69 (Approximate 20/40 Snellen Equivalent) at Weeks 36 and 64
ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)
Time frame: At Weeks 36 and 64
Participants Having no Intraretinal Fluid (IRF) and no Sub-retinal Fluid (SRF) in the Center Subfield at Weeks 36 and 64
Number of participants with no retinal fluid (no IRF and no SRF) in the central subfield at Weeks 36 and 64
Time frame: At Weeks 36 and 64
Change From Baseline in Central Sub-field Thickness (CST) at Week 36
Time frame: From baseline to Week 36
Change From Baseline in Central Sub-field Thickness (CST) at Week 64
Time frame: From baseline to Week 64
Change From Baseline in NEI VFQ 25 Total Score at Week 36
NEI-VFQ-25: National Eye Institute Visual Functioning Questionnaire-25; The NEI VFQ-25 total score ranges from 0 to 100. A higher score means a better outcome (better patient-reported visual function).
Time frame: From baseline to Week 36
Change From Baseline in NEI VFQ 25 Total Score at Week 64
NEI-VFQ-25: National Eye Institute Visual Functioning Questionnaire-25; The NEI VFQ-25 total score ranges from 0 to 100. A higher score means a better outcome (better patient-reported visual function).
Time frame: From baseline at Week 64
Participants Dosed Only Q8 Through Week 36 in the 8 mg Q8 Group
Number of participants in the aflibercept 8q8/3 and the aflibercept 8q8/5 groups who were able to maintain every 8 weeks (Q8) dosing through Week 36. Only participants who did not discontinue study intervention prior to Week 36, and were therefore considered "completers" for Week 36, were included in the analysis of this endpoint.
Time frame: Through Week 36
Participant Having Last Treatment Interval ≥12 or of 16 Weeks at Week 64
The proportion of participants having last completed treatment interval ≥12 or of 16 weeks at Week 64 for Week 64 completers.
Time frame: At Week 64
Participant Having Next Intended Interval ≥12, ≥16 or of 20 Weeks at Week 64
The proportion of participants having last intended treatment interval ≥12, ≥16 or 20 weeks at Week 64 for Week 64 completers.
Time frame: At Week 64
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Through Weeks 36 and 64
TEAEs were defined as AEs that occurred in the time frame from first injection (active or sham) to the last injection (active or sham) plus 30 days. Ocular TEAEs in study eye and non-ocular TEAEs are included (ocular TEAEs in fellow eye are excluded)
Time frame: Through Weeks 36 and 64
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Weeks 36 and 64
Total aflibercept is the sum of free and adjusted bound aflibercept.
Time frame: From baseline through Week 36 and 64
The study was conducted at 237 centers in Europe, America, Japan, and Asia-Pacific between 15-May-2023 (first participant first visit) and 27-May-2025 (last participant last visit) (Week 64).
| Milestone | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 |
|---|---|---|---|
| Started | 301 | 293 | 298 |
| Completed | 270 | 268 | 256 |
| Not completed | 31 | 25 | 42 |
| Withdrew: Withdrawal by subject | 18 | 13 | 28 |
| Withdrew: Lost to follow-up | 5 | 4 | 5 |
| Withdrew: Death | 3 | 2 | 5 |
| Withdrew: Adverse event | 3 | 2 | 3 |
| Withdrew: Physician decision | 0 | 2 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 1 |
| Withdrew: Logistical problem | 2 | 2 | 0 |
BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)
| Letters | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 |
|---|---|---|---|
| Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 36 | 17.5 ± 0.7 | 17.4 ± 0.7 | 18.3 ± 0.6 |
Active injections refer to the number of injections that were actually administered, as opposed to the number of planned injections.
| Number of active injections | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 |
|---|---|---|---|
| Number of Active Injections From Baseline to Week 64 | 11.7 ± 0.1 | 8.5 ± 0.1 | 9.5 ± 0.1 |
Active injections refer to the number of injections that were actually administered, as opposed to the number of planned injections.
| Number of active injections | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 |
|---|---|---|---|
| Number of Active Injections From Baseline to Week 36 | 8.8 ± 0.0 | 6.1 ± 0.0 | 6.9 ± 0.0 |
BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity). \*This endpoint was only measured for the 8q8/5 and 2q4 groups
| Letters | Aflibercept 2q4 | Aflibercept 8q8/5 |
|---|---|---|
| Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 44* | 17.8 ± 0.7 | 18.8 ± 0.7 |
BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)
| Letters | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 |
|---|---|---|---|
| Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 64 | 17.3 ± 0.8 | 17.8 ± 0.7 | 18.1 ± 0.8 |
| Participants | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 |
|---|---|---|---|
| Number of participants who gained at least 15 letters in BCVA at Week 36 | 158 | 153 | 161 |
| Number of participants who gained at least 15 letters in BCVA at Week 64 | 154 | 156 | 161 |
ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)
| Participants | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 |
|---|---|---|---|
| Participants who achieved letter score of at least 69 letters at Week 36 | 179 | 189 | 189 |
| Participants who achieved letter score of at least 69 letters at Week 64 | 179 | 178 | 181 |
Number of participants with no retinal fluid (no IRF and no SRF) in the central subfield at Weeks 36 and 64
| Participants | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 |
|---|---|---|---|
| Participants with no IRF and no SRF in central subfield at Week 36 | 221 | 211 | 202 |
| Participants with no IRF and no SRF in central subfield at Week 64 | 167 | 193 | 171 |
| μm | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 |
|---|---|---|---|
| Change From Baseline in Central Sub-field Thickness (CST) at Week 36 | -370.8 ± 3.9 | -370.9 ± 3.1 | -369.5 ± 2.3 |
| μm | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 |
|---|---|---|---|
| Change From Baseline in Central Sub-field Thickness (CST) at Week 64 | -353.7 ± 5.2 | -361.1 ± 4.3 | -353.3 ± 4.1 |
NEI-VFQ-25: National Eye Institute Visual Functioning Questionnaire-25; The NEI VFQ-25 total score ranges from 0 to 100. A higher score means a better outcome (better patient-reported visual function).
| Scores on a scale | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 |
|---|---|---|---|
| Change From Baseline in NEI VFQ 25 Total Score at Week 36 | 6.27 ± 0.67 | 5.91 ± 0.61 | 6.92 ± 0.63 |
NEI-VFQ-25: National Eye Institute Visual Functioning Questionnaire-25; The NEI VFQ-25 total score ranges from 0 to 100. A higher score means a better outcome (better patient-reported visual function).
| Scores on a scale | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 |
|---|---|---|---|
| Change From Baseline in NEI VFQ 25 Total Score at Week 64 | 7.21 ± 0.60 | 6.10 ± 0.66 | 6.67 ± 0.63 |
Number of participants in the aflibercept 8q8/3 and the aflibercept 8q8/5 groups who were able to maintain every 8 weeks (Q8) dosing through Week 36. Only participants who did not discontinue study intervention prior to Week 36, and were therefore considered "completers" for Week 36, were included in the analysis of this endpoint.
| Participants | Aflibercept 8q8/3 | Aflibercept 8q8/5 | All Aflibercept 8 mg |
|---|---|---|---|
| Participants Dosed Only Q8 Through Week 36 in the 8 mg Q8 Group | 246 | 255 | 501 |
The proportion of participants having last completed treatment interval ≥12 or of 16 weeks at Week 64 for Week 64 completers.
| Participants | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 |
|---|---|---|---|
| Last completed dosing interval ≥Q12 | 183 | 219 | 201 |
| Last completed dosing interval Q16 | — | 151 | — |
The proportion of participants having last intended treatment interval ≥12, ≥16 or 20 weeks at Week 64 for Week 64 completers.
| Participants | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 |
|---|---|---|---|
| Last intended dosing interval ≥Q12 | 210 | 232 | 219 |
| Last intended dosing interval ≥Q16 | 135 | 173 | 159 |
| Last intended dosing interval Q20 | — | 109 | — |
TEAEs were defined as AEs that occurred in the time frame from first injection (active or sham) to the last injection (active or sham) plus 30 days. Ocular TEAEs in study eye and non-ocular TEAEs are included (ocular TEAEs in fellow eye are excluded)
| Participants | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 | All Aflibercept HD |
|---|---|---|---|---|
| Number of participants with TEAEs at Week 36 | 188 | 184 | 176 | 360 |
| Number of participants with TESAEs at Week 36 | 32 | 23 | 26 | 49 |
| Number of participants with TEAEs at Week 64 | 226 | 220 | 211 | 431 |
| Number of participants with TESAEs at Week 64 | 44 | 37 | 38 | 75 |
Total aflibercept is the sum of free and adjusted bound aflibercept.
| ng/mL | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 |
|---|---|---|---|
| Week 4 | 91.6 ± 55.82 | 281.8 ± 52.16 | 270.7 ± 63.78 |
| Week 12 | 151.5 ± 56.99 | 451.7 ± 58.83 | 452.6 ± 57.04 |
| Week 16 | 241.6 ± 48.33 | 470.5 ± 58.24 | 728.0 ± 43.80 |
| Week 24 | 164.1 ± 61.42 | 179.1 ± 73.00 | 202.5 ± 80.94 |
| Week 36 | 176.4 ± 63.65 | 373.9 ± 61.16 | 356.9 ± 71.10 |
| Week 64 | NA ± NA | 197.5 ± 123.33 | 87.4 ± 145.01 |
Collected over Adverse events (AEs) were collected from baseline through Week 64, from first injection (active or sham) up to 4 weeks after last injection (active or sham). AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept 2q4 | 3/301 (1%) | 44/301 (14.6%) | 226/301 (75.1%) |
| Aflibercept 8q8/3 | 2/293 (0.7%) | 37/293 (12.6%) | 220/293 (75.1%) |
| Aflibercept 8q8/5 | 5/298 (1.7%) | 38/298 (12.8%) | 211/298 (70.8%) |
| All Aflibercept 8mg | 7/591 (1.2%) | 75/591 (12.7%) | 431/591 (72.9%) |
| Event | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 | All Aflibercept 8mg |
|---|---|---|---|---|
| EndophthalmitisInfections and infestations | 3/301 | 1/293 | 0/298 | 1/591 |
| BradycardiaCardiac disorders | 0/301 | 2/293 | 0/298 | 2/591 |
| DiverticulitisInfections and infestations | 0/301 | 2/293 | 0/298 | 2/591 |
| SepsisInfections and infestations | 0/301 | 2/293 | 0/298 | 2/591 |
| BradycardiaCardiac disorders | 0/301 | 2/293 | 0/298 | 2/591 |
| DiverticulitisInfections and infestations | 0/301 | 2/293 | 1/298 | 3/591 |
| PneumoniaInfections and infestations | 2/301 | 2/293 | 1/298 | 3/591 |
| SepsisInfections and infestations | 0/301 | 2/293 | 1/298 | 3/591 |
| Macular holeEye disorders | 2/301 | 0/293 | 0/298 | 0/591 |
| EndophthalmitisInfections and infestations | 2/301 | 1/293 | 0/298 | 1/591 |
| Event | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 | All Aflibercept 8mg |
|---|---|---|---|---|
| HypertensionVascular disorders | 15/301 | 31/293 | 25/298 | 56/591 |
| NasopharyngitisInfections and infestations | 20/301 | 25/293 | 27/298 | 52/591 |
| HypertensionVascular disorders | 10/301 | 19/293 | 20/298 | 39/591 |
| Intraocular pressure increasedInvestigations | 8/301 | 19/293 | 16/298 | 35/591 |
| CataractEye disorders | 17/301 | 11/293 | 17/298 | 28/591 |
| Intraocular pressure increasedInvestigations | 5/301 | 16/293 | 15/298 | 31/591 |
| Visual acuity reducedEye disorders | 11/301 | 16/293 | 8/298 | 24/591 |
| COVID-19Infections and infestations | 8/301 | 16/293 | 12/298 | 28/591 |
| NasopharyngitisInfections and infestations | 9/301 | 15/293 | 14/298 | 29/591 |
| Conjunctival haemorrhageEye disorders | 8/301 | 14/293 | 12/298 | 26/591 |
| Age, Continuous(Years) | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 | Total |
|---|---|---|---|---|
| Mean | 65.9 ± 11.7 | 65.8 ± 11.5 | 65.8 ± 11.5 | 65.9 ± 11.6 |
| Sex: Female, Male(Participants) | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 | Total |
|---|---|---|---|---|
| Female | 144 | 136 | 146 | 426 |
| Male | 157 | 157 | 152 | 466 |
| Ethnicity (NIH/OMB)(Participants) | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 22 | 25 | 14 | 61 |
| Not Hispanic or Latino | 267 | 254 | 273 | 794 |
| Unknown or Not Reported | 12 | 14 | 11 | 37 |
| Race/Ethnicity, Customized(Participants) | Aflibercept 2q4 | Aflibercept 8q8/3 | Aflibercept 8q8/5 | Total |
|---|---|---|---|---|
| American Indian or Alaskan Native | 0 | 0 | 2 | 2 |
| Asian | 101 | 91 | 97 | 289 |
| Black or African American | 8 | 7 | 9 | 24 |
| Multiple | 1 | 0 | 1 | 2 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 1 | 1 |
| Not reported | 13 | 22 | 11 | 46 |
| White | 178 | 173 | 177 | 528 |
Showing the first 100 of 273 sites across 27 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from May 2023 to primary completion in Nov 2024, 17 months.
Results were first posted in Dec 2025, 1 year 1 month after primary completion.
Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 17 months is below that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.